π SIGNAL REMINDER
π± $SVRA Β· Phase 2 β Phase 3
LONG-term Β· conviction 75/100
Entry $4.71β$4.75 β Target $6.24β$7.00
π Floating P&L: +9.41% (+$94.08)
SVRA is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $4.73 (Β±0.5%) to absorb intraday noise, while the target band of $6.24β$7.00 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (1 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#SVRA #Savara #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π FRESH SIGNAL
π± $KOD Β· Phase 2 β Phase 3
LONG-term Β· conviction 75/100
Entry $97.31β$98.28 β Target $129.09β$144.74
KOD is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 7 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $97.80 (Β±0.5%) to absorb intraday noise, while the target band of $129.09β$144.74 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#KOD #Kodiak #KodiakSciences #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π FRESH SIGNAL
π± $MIRM Β· Phase 2 β Phase 3
LONG-term Β· conviction 80/100
Entry $92.13β$93.05 β Target $122.22β$137.03
MIRM is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $92.59 (Β±0.5%) to absorb intraday noise, while the target band of $122.22β$137.03 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#MIRM #Mirum #MirumPharmaceuticals #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $INSM Β· Phase 2 β Phase 3
LONG-term Β· conviction 80/100
Entry $111.69β$112.82 β Target $148.18β$166.14
π Floating P&L: +6.74% (+$67.39)
INSM is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $112.25 (Β±0.5%) to absorb intraday noise, while the target band of $148.18β$166.14 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#INSM #Insmed #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π SIGNAL REMINDER
π± $BMRN Β· Phase 2 β Phase 3
LONG-term Β· conviction 73/100
Entry $56.73β$57.30 β Target $75.26β$84.38
π Floating P&L: +7.67% (+$76.73)
BMRN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 94/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $57.02 (Β±0.5%) to absorb intraday noise, while the target band of $75.26β$84.38 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (14 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#BMRN #Biomarin #BiomarinPharmaceutical #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $LPCN Β· Phase 2 οΏ½οΏ½οΏ½ Phase 3
LONG-term Β· conviction 79/100
Entry $1.45β$1.46 β Target $1.92β$2.15
π Floating P&L: +7.56% (+$75.60)
LPCN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 9 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $1.46 (Β±0.5%) to absorb intraday noise, while the target band of $1.92β$2.15 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#LPCN #Lipocine #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π SIGNAL REMINDER
π± $URGN Β· Phase 2 β Phase 3
LONG-term Β· conviction 79/100
Entry $26.19β$26.45 β Target $34.74β$38.95
π Floating P&L: +13.30% (+$132.98)
URGN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $26.32 (Β±0.5%) to absorb intraday noise, while the target band of $34.74β$38.95 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#URGN #UroGen #UroGenPharma #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $VTGN Β· Phase 2 β Phase 3
LONG-term Β· conviction 75/100
Entry $0.18β$0.18 β Target $0.24β$0.27
π Floating P&L: +10.34% (+$103.39)
VTGN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 8 active trial(s) (score 94/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $0.18 (Β±0.5%) to absorb intraday noise, while the target band of $0.24β$0.27 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (1 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#VTGN #Vistagen #VistagenTherapeutics #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $BMRN Β· Phase 2 β Phase 3
LONG-term Β· conviction 73/100
Entry $56.73β$57.30 β Target $75.26β$84.38
π Floating P&L: +7.67% (+$76.73)
BMRN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 94/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $57.02 (Β±0.5%) to absorb intraday noise, while the target band of $75.26β$84.38 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (14 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#BMRN #Biomarin #BiomarinPharmaceutical #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $INCY Β· Phase 2 β Phase 3
LONG-term Β· conviction 76/100
Entry $113.40β$114.54 β Target $150.44β$168.68
π Floating P&L: +3.36% (+$33.61)
INCY is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $113.97 (Β±0.5%) to absorb intraday noise, while the target band of $150.44β$168.68 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (35 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#INCY #Incyte #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π SIGNAL REMINDER
π± $URGN Β· Phase 2 β Phase 3
LONG-term Β· conviction 79/100
Entry $26.19β$26.45 β Target $34.74β$38.95
π Floating P&L: +13.30% (+$132.98)
URGN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $26.32 (Β±0.5%) to absorb intraday noise, while the target band of $34.74β$38.95 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#URGN #UroGen #UroGenPharma #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $ABBV Β· Phase 2 β Phase 3
LONG-term Β· conviction 80/100
Entry $283.33β$286.18 β Target $375.88β$421.44
π Floating P&L: +0.44% (+$4.41)
ABBV is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $284.75 (Β±0.5%) to absorb intraday noise, while the target band of $375.88β$421.44 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (207 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#ABBV #AbbVie #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π FRESH SIGNAL
π± $DNLI Β· Phase 2 β Phase 3
LONG-term Β· conviction 65/100
Entry $18.26β$18.44 β Target $24.22β$27.16
DNLI is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 82/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $18.35 (Β±0.5%) to absorb intraday noise, while the target band of $24.22β$27.16 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (12 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#DNLI #Denali #DenaliTherapeutics #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $VTGN Β· Phase 2 β Phase 3
LONG-term Β· conviction 75/100
Entry $0.18β$0.18 β Target $0.24β$0.27
π Floating P&L: +6.73% (+$67.26)
VTGN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 8 active trial(s) (score 94/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $0.18 (Β±0.5%) to absorb intraday noise, while the target band of $0.24β$0.27 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (1 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#VTGN #Vistagen #VistagenTherapeutics #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π FRESH SIGNAL
π± $ABEO Β· Phase 2 β Phase 3
LONG-term Β· conviction 83/100
Entry $2.73β$2.75 β Target $3.62β$4.06
ABEO is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 8 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $2.74 (Β±0.5%) to absorb intraday noise, while the target band of $3.62β$4.06 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#ABEO #Abeona #AbeonaTherapeutics #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL UPDATE
π± $ADRX Β· Phase 2 β Phase 3
LONG-term Β· conviction 68/100
Entry $14.04β$14.18 β Target $18.63β$20.88
π Floating P&L: +5.03% (+$50.32)
ADRX is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 9 active trial(s) (score 82/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $14.11 (Β±0.5%) to absorb intraday noise, while the target band of $18.63β$20.88 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (1 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#ADRX #ADARx #ADARxPharmaceuticals #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $BMRN Β· Phase 2 β Phase 3
LONG-term Β· conviction 73/100
Entry $56.73β$57.30 β Target $75.26β$84.38
π Floating P&L: +2.64% (+$26.40)
BMRN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 94/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $57.02 (Β±0.5%) to absorb intraday noise, while the target band of $75.26β$84.38 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (14 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#BMRN #Biomarin #BiomarinPharmaceutical #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
π SIGNAL REMINDER
π± $LPCN Β· Phase 2 β Phase 3
LONG-term Β· conviction 79/100
Entry $1.45β$1.46 β Target $1.92β$2.15
π Floating P&L: +10.65% (+$106.53)
LPCN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 9 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $1.46 (Β±0.5%) to absorb intraday noise, while the target band of $1.92β$2.15 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#LPCN #Lipocine #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π SIGNAL REMINDER
π± $EXEL Β· Phase 2 β Phase 3
LONG-term Β· conviction 76/100
Entry $62.72β$63.36 β Target $83.21β$93.30
π Floating P&L: +8.66% (+$86.61)
EXEL is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $63.04 (Β±0.5%) to absorb intraday noise, while the target band of $83.21β$93.30 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#EXEL #Exelixis #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks #FinTwit
π SIGNAL REMINDER
π± $URGN Β· Phase 2 β Phase 3
LONG-term Β· conviction 79/100
Entry $26.19β$26.45 β Target $34.74β$38.95
π Floating P&L: +13.60% (+$136.02)
URGN is classified as a LONG-term catalyst play (~42 calendar days). A deep clinical pipeline of 10 active trial(s) (score 100/100) points to a catalyst that is real but further out, which is why the holding window is set to ~42 calendar days. The entry band brackets the current spot of $26.32 (Β±0.5%) to absorb intraday noise, while the target band of $34.74β$38.95 reflects a ~+40% expansion scaled to the catalyst's strength and horizon. PubMed publication activity (0 recent) and limited retail-sentiment signal were folded into the sentiment vector. β¦
β Not financial advice Β· @moleculexx
#URGN #UroGen #UroGenPharma #Phase3 #FDA #Catalyst #ScienceTwitter #LongTermInvesting #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks